Article
<i>ERBB2</i> / <i>HOXB13</i> co-amplification with interstitial deletion of <i>BRCA1</i> defines a unique subset of breast cancers
2024-08-07
Abstract excerpt
<h4>Background</h4> The HOXB13/IL17BR gene expression biomarker has been shown to predict response to adjuvant and extended endocrine therapy in patients with early-stage ER+ HER2- breast tumors. HOXB13 gene expression is the primary determinant driving the prognostic and endocrine treatment-predictive performance of the biomarker. Currently, there is limited data on HOXB13 expression in HER2+ and ER- breast c...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1066c642-9d06-5b2f-b1b1-6843b11b60a8
- DOI
- 10.1101/2024.08.04.605361
